Francesca Schiavi

List of Publications by Year
in descending order

71 papers	4,988 citations	117625 34 h-index	106344 65 g-index
72 all docs	72 docs citations	72 times ranked	5187 citing authors

#	Article	IF	Citations
1	Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genetics, 2011, 43, 663-667.	21.4	478
2	Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature Genetics, 2010, 42, 229-233.	21.4	364
3	Predictors and Prevalence of Paraganglioma Syndrome Associated With Mutations of the <EMPH TYPE="ITAL">SDHC</EMPH> Gene. JAMA - Journal of the American Medical Association, 2005, 294, 2057.	7.4	309
4	Clinically Guided Genetic Screening in a Large Cohort of Italian Patients with Pheochromocytomas and/or Functional or Nonfunctional Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1541-1547.	3.6	284
5	MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837.	7.0	277
6	Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartateÂbiosynthesis. Nature Cell Biology, 2015, 17, 1317-1326.	10.3	226
7	Surgical Versus Conservative Management for Subclinical Cushing Syndrome in Adrenal Incidentalomas: A Prospective Randomized Study. Annals of Surgery, 2009, 249, 388-391.	4.2	205
8	Research Resource: Transcriptional Profiling Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas. Molecular Endocrinology, 2010, 24, 2382-2391.	3.7	179
9	Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out. Cancer Research, 2009, 69, 3650-3656.	0.9	178
10	Spectrum and Prevalence of FP/TMEM127 Gene Mutations in Pheochromocytomas and Paragangliomas. JAMA - Journal of the American Medical Association, 2010, 304, 2611.	7.4	174
11	Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention. JAMA Oncology, 2017, 3, 1204.	7.1	149
12	The Variant rs1867277 in FOXE1 Gene Confers Thyroid Cancer Susceptibility through the Recruitment of USF1/USF2 Transcription Factors. PLoS Genetics, 2009, 5, e1000637.	3.5	140
13	Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncology, The, 2014, 15, 648-655.	10.7	137
14	GermlineNF1Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2784-2792.	3.6	126
15	Long-term prognosis of patients with pediatric pheochromocytoma. Endocrine-Related Cancer, 2014, 21, 17-25.	3.1	121
16	Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3903-3911.	3.6	111
17	Cardiovascular Risk Factors and Ultrasound Evaluation of Intima-Media Thickness at Common Carotids, Carotid Bulbs, and Femoral and Abdominal Aorta Arteries in Patients with Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1015-1018.	3.6	109
18	Elevated Expression of Luteinizing Hormone Receptor in Aldosterone-Producing Adenomas. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1136-1142.	3.6	89

#	Article	IF	Citations
19	Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy. JAMA Network Open, 2019, 2, e198898.	5.9	80
20	Gain-of-function mutations in DNMT3A in patients with paraganglioma. Genetics in Medicine, 2018, 20, 1644-1651.	2.4	73
21	Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Individuals with Neck or Mediastinal Paraganglioma (PGL). Hormone and Metabolic Research, 2012, 44, 411-414.	1.5	71
22	Are we overestimating the penetrance of mutations in SDHB?. Human Mutation, 2010, 31, 761-762.	2.5	64
23	Genetics of pheochromocytomas and paragangliomas. Best Practice and Research in Clinical Endocrinology and Metabolism, 2010, 24, 943-956.	4.7	62
24	Pheochromocytoma in von Hippelâ€“Lindau disease and neurofibromatosis type 1. Familial Cancer, 2005, 4, 13-16.	1.9	57
25	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clinical Cancer Research, 2015, 21, 3020-3030.	7.0	53
26	Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocrine-Related Cancer, 2013, 20, 477-493.	3.1	52
27	65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma. Endocrine-Related Cancer, 2018, 25, T201-T219.	3.1	52
28	Characterization of endolymphatic sac tumors and von Hippelâ€“Lindau disease in the International Endolymphatic Sac Tumor Registry. Head and Neck, 2016, 38, E673-9.	2.0	48
29	Parathyroid Scintigraphy in Renal Hyperparathyroidism. Clinical Nuclear Medicine, 2013, 38, 630-635.	1.3	47
30	Thyroid cancer <scp>GWAS</scp> identifies 10q26.12 and 6q14.1 as novel susceptibility loci and reveals genetic heterogeneity among populations. International Journal of Cancer, 2015, 137, 1870-1878.	5.1	44
31	Preventive medicine of von Hippelâ€“Lindau disease-associated pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 783-793.	3.1	42
32	ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions. Journal of Human Hypertension, 2016, 30, 374-378.	2.2	38
33	Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. Lancet Diabetes and Endocrinology,the, 2021, 9, 13-21.	11.4	37
34	Von Hippel-Lindau disease: an evaluation of natural history and functional disability. Neuro-Oncology, 2016, 18, 1011-1020.	1.2	36
35	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. Clinical Cancer Research, 2022, 28, 308-317.	7.0	36
36	Differential Gene Expression of Medullary Thyroid Carcinoma Reveals Specific Markers Associated with Genetic Conditions. American Journal of Pathology, 2013, 182, 350-362.	3.8	35

#	Article	IF	Citations
37	Paraganglioma Syndrome: SDHB, SDHC, and SDHD Mutations in Head and Neck Paragangliomas. Annals of the New York Academy of Sciences, 2006, 1073, 190-197.	3.8	31
38	A registry-based study of thyroid paraganglioma: histological and genetic characteristics. Endocrine-Related Cancer, 2015, 22, 191-204.	3.1	29
39	Is genetic screening indicated in apparently sporadic pheochromocytomas and paragangliomas?. Surgery, 2011, 150, 1194-1201.	1.9	26
40	The Endemic Paraganglioma Syndrome Type 1: Origin, Spread, and Clinical Expression. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E637-E641.	3.6	25
41	Functional and in silico assessment of MAX variants of unknown significance. Journal of Molecular Medicine, 2015, 93, 1247-1255.	3.9	25
42	Role of ultrasound and color Doppler imaging in the detection of carotid paragangliomas. Journal of Ultrasound, 2012, 15, 158-163.	1.3	20
43	18F-DOPA PET/CT in the Evaluation of Hereditary SDH-Deficiency Paraganglioma-Pheochromocytoma Syndromes. Clinical Nuclear Medicine, 2014, 39, e53-e58.	1.3	20
44	Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib. Acta Neuropathologica, 2018, 135, 779-798.	7.7	20
45	Fine analysis of the short arm of chromosome 1 in sporadic and familial pheochromocytoma. Clinical Endocrinology, 2003, 59, 707-715.	2.4	19
46	Peptide Receptor Radionuclide Therapy in a Case of Multiple Spinal Canal and Cranial Paragangliomas. Journal of Clinical Oncology, 2011, 29, e171-e174.	1.6	19
47	A Novel MAX Gene Mutation Variant in a Patient With Multiple and â€œCompositeâ€• Neuroendocrineâ€“Neuroblastic Tumors. Frontiers in Endocrinology, 2020, 11, 234.	3.5	18
48	Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma. Anti-Cancer Drugs, 2018, 29, 102-105.	1.4	17
49	Clinical and Genetic Aspects of Phaeochromocytoma. Hormone Research in Paediatrics, 2003, 59, 56-61.	1.8	16
50	Familial Nonsyndromic Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 149-155.	3.8	15
51	Functional Consequences of Succinate Dehydrogenase Mutations. Endocrine Practice, 2011, 17, 64-71.	2.1	15
52	First steps to define murine amniotic fluid stem cell microenvironment. Scientific Reports, 2016, 6, 37080.	3.3	11
53	An Epistatic Interaction between the PAX8 and STK17B Genes in Papillary Thyroid Cancer Susceptibility. PLoS ONE, 2013, 8, e74765.	2.5	9
54	Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation. Medicine (United States), 2018, 97, e10904.	1.0	9

#	Article	IF	Citations
55	Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma. Frontiers in Oncology, 2020, 10, 567289.	2.8	8
56	The M235T polymorphism of the angiotensinogen gene in women with polycystic ovary syndrome. Fertility and Sterility, 2005, 84, 1520-1521.	1.0	7
57	Loss of BAP1 in Pheochromocytomas and Paragangliomas Seems Unrelated to Genetic Mutations. Endocrine Pathology, 2019, 30, 276-284.	9.0	7
58	Role of SDHAF2 and SDHD in von Hippelâ€“Lindau Associated Pheochromocytomas. World Journal of Surgery, 2014, 38, 724-732.	1.6	6
59	Improving Outcomes in Carotid Body Tumors Treatment: The Impact of a Multidisciplinary Team Approach. Annals of Vascular Surgery, 2021, 75, 315-323.	0.9	6
60	Concurrent pheochromocytoma and cortical carcinoma of the adrenal gland. Journal of Surgical Oncology, 2011, 103, 103-104.	1.7	5
61	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. Cancers, 2021, 13, 5831.	3.7	5
62	Multi-Design Differential Expression Profiling of COVID-19 Lung Autopsy Specimens Reveals Significantly Deregulated Inflammatory Pathways and SFTPC Impaired Transcription. Cells, 2022, 11, 1011.	4.1	5
63	Tympanojugular Paragangliomas: Surgical Management and Clinicopathological Features. , 0, , 99-123.		4
64	Overexpression of miR-375 and L-type Amino Acid Transporter 1 in Pheochromocytoma and Their Molecular and Functional Implications. International Journal of Molecular Sciences, 2022, 23, 2413.	4.1	4
65	The pheochromocytoma and paraganglioma syndrome: Founder effects and the PGL 1 syndrome. Annales D'Endocrinologie, 2009, 70, 157-160.	1.4	3
66	Liquid Biopsy in Pediatric Renal Cancer: Stage I and Stage IV Cases Compared. Diagnostics, 2020, 10, 810.	2.6	1
67	Diagnosi e terapia della sindrome paraganglioma. L Endocrinologo, 2011, 12, 170-178.	0.0	0
68	Pheochromocytomas in Complex Genetic Disorders. Endocrinology, 2021, , 325-344.	0.1	0
69	Von Hippel-Lindau disease and multispecialist team. Journal of Neurosurgical Sciences, 2021, 65, 213-215.	0.6	0
70	Prevention Medicine in Bilateral Phaeochromocytoma. SSRN Electronic Journal, 0, , .	0.4	0
71	Pheochromocytomas in Complex Genetic Disorders. Endocrinology, 2019, , 1-20.	0.1	0